Busulphan (Myleran) introduced in 1953 as an alkylating agent is the drug of choice in the treatment of chronic myeloid leukemia. Cataract as a toxic effect caused by prolonged busulphan therapy has been rarely reported [1-3].

In this paper, a patient with chronic myeloid leukemia who developed mature cataract in both eyes during prolonged busulphan therapy is presented.

In April 1985, the woman noted failure of vision first in her right eye and 3 months later in her left eye. On examination, this was found to be due to an early cataract. In October 1985, the patient was admitted again to our hospital because of fever (37.5°C), tiredness and failure of vision in both eyes. On physical examination, multiple small lymph nodes were palpable in her cervical region. Sternal tenderness was present. The spleen was palpable 4 cm below the left costal margin. Hyperpigmentation around both eyes, elbows and the abdomen was
observed. In addition, skin lesions due to herpes zoster were found on the right side of her thorax. Mature cataract was present in both her eyes. The hematocrit value was 21%, reticulocytes 3%. The morphologic features of the red cells in the blood film showed anisocytosis, severe poikilocytosis, poly-chromasia and basophilic stippling. The leukocyte count was 15,600/mm³. Differential leukocyte count showed leukoerythro-blastosis; the platelet count was 400,000/mm³. Bone marrow aspi-

Discussion
The patient presented in this report had been taking 1-2 mg of busulphan daily from 1979 until 1985, when she first noticed failure of vision. No reason other than the prolonged busulphan therapy was found to be the cause of her cataract. When the patient was admitted to our hospital for the second time, her general condition did not allow operation for her cataract.

References